Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

IMPORTANCE: Limited information is available on the safety of a rechallenge with an immune checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). OBJECTIVE: To identify the recurrence rate of the same irAE that prompted discontinuation of ICI therapy after an ICI rechallenge in pat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Dolladille, Charles, Ederhy, Stéphane, Sassier, Marion, Cautela, Jennifer, Thuny, Franck, Cohen, Ariel A., Fedrizzi, Sophie, Chrétien, Basile, Da-Silva, Angélique, Plane, Anne-Flore, Legallois, Damien, Milliez, Paul U., Lelong-Boulouard, Véronique, Alexandre, Joachim
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7163782/
https://ncbi.nlm.nih.gov/pubmed/32297899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.0726
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados